Our GWAS identified 423 significant risk variants located in 31 genes, including 6 variants previously reported to be associated with NAFLD located on GCKR, LPL, TRIB1AL, and FTO. The primary aim of our discovery study was to identify genetic variants associated with FLD in a Taiwanese cohort using FLI as a diagnostic tool. The gene discussed is LPL; the disease is metabolic dysfunction-associated steatotic liver disease.